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Extracellular vesicles (EVs) appear as important actors in cell-to-cell communication. EV content is
characterized by proteins and RNA species that dynamically reﬂect cell and tissue state. Urinary EVs in
particular may act in inter-nephron communication with possible beneﬁcial or detrimental effects. In-
creasing interest is addressed to the pharmacological properties of EVs as a cell-free therapy, since
several of the effects crAQ/tgqcedited to stem cells have been recapitulated by administration of their
EVs. Preclinical data in models of renal damage indicate a general regenerative potential of EVs derived
from mesenchymal stromal cells of different sources, including bone marrow, fetal tissues, urine and
kidney. In this review we will discuss the results on the effect of EVs in repair of acute and chronic renal
injury, and the mechanisms involved. In addition, we will analyse the strategies for EV pharmacological
applications in renal regenerative medicine and limits and beneﬁts involved.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Intercellular communication plays a key role in the regulation
of tissue organization and functions of multicellular organisms.
During the last years, extracellular vesicles (EVs) have been dis-
covered as important actors in cell-to-cell interaction. Indeed,
these small vesicles, secreted by cells and present in almost every
body ﬂuid, appear as an ancestral mechanism of communication
among cells and tissues (Valadi et al., 2007).
EVs act on target cells in different ways, including cell stimu-
lation, transfer of genetic material, mainly messenger RNA (mRNA)
and microRNAs (miRNAs), but also of proteins and lipids to target
cells, even at distant sites (Nawaz et al., 2016). As a result, EVs may
modify target cells and reprogram their biological function with a
long lasting outcome (Bruno and Camussi, 2013). Several evi-
dences show the implication of EVs in controlling physiological
processes such as stem cell maintenance (Ratajczak et al., 2006),
tissue repair (Gatti et al., 2011) and immune surveillance (Lugini
et al., 2012). In addition, in pathology, EVs appear as a mechanism
to amplify and propagate diseases. Examples were shown in Par-
kinson and Alzheimer diseases (Bellingham et al., 2012; Emma-
nouilidou et al., 2010), tumorigenesis (Rak and Guha, 2012) or
primary hypertension (Aliotta et al., 2016). On the other side, in-
creasing interest is addressed to the pharmacological properties of
EVs as a cell-free therapy, since several of the effects credited toB.V. This is an open access article u
tre, University of Torino, via
ussolati).stem cells have been recapitulated by administration of their EVs.
In this review, we will focus on the role of EVs in renal pa-
thology and repair. We will ﬁrst discuss the data of the literature
on the role of urine-derived EVs (uEVs) within the nephron as
tools for inter-nephron communication, repair or damage. More-
over, we will describe the preclinical data on the use of stem-cell
derived EVs for therapeutic applications in renal pathology, and
the mechanisms involved. Finally, we will dissect the strategies for
EV pharmacological applications, and limits and beneﬁts involved.2. General characteristics of EVs
2.1. EV biogenesis
EVs appear to be released from nearly all mammalian cell
types. Among the most studied cell types are stem cells and pro-
genitors (Lai et al., 2011; Ratajczak et al., 2006), primary cells of
the immune and nervous systems (Chavez-Muñoz et al., 2008;
Potolicchio et al., 2005) as well as numerous cancer cell lines (Al-
Nedawi et al., 2009; Nakano et al., 2015). In addition, EVs have
been isolated from the majority of biological ﬂuids (Keller et al.,
2011; Lässer et al., 2011; Wang and Sun, 2014; EL Andaloussi et al.,
2013; Turturici et al., 2014).
Although distinct biogenesis pathways lead to different types of
extracellular vesicles, EVs could be grouped in three main classes:
exosomes, microvesicles and apoptotic bodies (Table 1) (Akers
et al., 2013; EL Andaloussi et al., 2013; Katsuda et al., 2013). Exo-
somes are an homogeneous population with a ranging size of 30–nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Summary of principal features of EVs.
Vesicles
types
Features
Source Size Markers Contents
Exosomes Endosomal origin and storage with subsequent
release by fusion of MVB to plasma membrane
30–150 nm Tetraspanins (CD9, CD63 and CD81),
ESCRT components, Alix and Tsg101
Cytoplasmic proteins with the presence of
mRNAs, miRNAs and other non-coding RNAs
Microvesicles Direct budding from plasma membrane 200–1000 nm Integrins, Selectins, Tetraspanins and
membrane related cell markers
Cytoplasmic proteins with the presence of
mRNAs, miRNAs and other non-coding RNAs
Apoptotic
Bodies
Fragmentation of plasma membrane during
apoptosis
1000–5000 nm Phosphatidyl-serine and membrane
related cell markers
Nuclear and organelles fragments, cyto-
plasmic proteins
EV population can be classiﬁed in exosomes, microvesicles and apoptotic bodies by different mechanism of generation. Other features of these EV classes such as dimension,
marker expression and content are reported.
Fig. 1. Schematic representation of biogenesis and release of extracellular vesicles. Extracellular vesicles can be classiﬁed into three main classes: exosomes, microvesicles
and apoptotic bodies. Exosomes are formed from inward budding of early endosomes and are subsequently release by the fusion of multivesicular bodies (MVB) to the
plasma membrane through the exocytosis pathway. Exosomes may contain several proteins and speciﬁc nucleic acids (mRNAs and miRNAs) and are highly enriched in
glycosphingolipids, sphingomyelin, cholesterol, and phosphatidyl-serine. MVB can also be degraded into lysosomes. On the other hand, microvesicles are formed from the
direct outward budding of the plasma membrane and they may transport RNA molecules and both membrane and cytoplasmic proteins. Apoptotic bodies are heterogeneous
in size and are formed by random blebbing of plasma membrane of cells undergoing apoptosis. Apoptotic bodies may contain membrane proteins, parts of cytoplasmic
organelles and nuclear fragments as well as a large amount of phosphatidyl-serine residues.
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they are stored and released by the fusion of multivesicular bodies
with the plasma membrane (Fig. 1) (Mathivanan et al., 2010).
While the correct assembly and sorting of exosomes remain not
completely clear, several mechanisms have been recently identi-
ﬁed in the regulation of exosomes biogenesis. These mechanisms
guide protein and RNA cargo sorting thus generating exosomes
with a precise biochemical composition (Baietti et al., 2012; Rai-
borg and Stenmark, 2009). In particular, cargo sorting into exo-
somes involves the Endosomal Sorting Complex Required for
Transport (ESCRT-3) and other associated proteins such as Apop-
tosis-Linked Gene-2-Interacting Protein X (Alix) and Tumour
Susceptibility Gene 101 (Tsg101). Microvesicles, also known as
shedding vesicles, are larger particles of 200–1000 nm in size, and
represent a relatively heterogeneous population of vesicles (EL
Andaloussi et al., 2013; Katsuda et al., 2013). Formation of shed-
ding vesicles takes place from the budding of small cytoplasmic
protrusions followed by their detachment from the plasma
membrane (Fig. 1). Therefore, it has been suggested that the
membrane composition of microvesicles reﬂects the one of the
parent cells in a closer fashion than that in exosomes (EL Anda-
loussi et al., 2013). Moreover, the microvesicle biogenesis is an
energy-dependent process, depending on calcium inﬂux and cy-
toskeleton reorganization (Cocucci et al., 2009). However, calciumis not the only second messenger involved in inducing vesicle
release as the activation by phorbol ester of Protein Kinase C has
also been showed to play a role in various cell types (Baj-Krzy-
worzeka et al., 2006). A third type of vesicles are the apoptotic
bodies, large 1000–5000 nm size particles released upon frag-
mentation of plasma membrane that occurs during apoptosis
(Akers et al., 2013) (Fig. 1). When referring to EVs, the majority of
studies comprise a heterogeneous population of exosomes and
microvesicles, whereas the apoptotic bodies are distinct in activity
and content.
2.2. EV isolation and characterization
EVs present in cell supernatants or biological ﬂuids represent a
heterogeneous population of vesicles. Common EV isolation pro-
tocols used include density gradient centrifugations and ultra-
centrifugation, polymer-based methods (used by some commer-
cial kits), chromatography, ﬁltration, and immunoafﬁnity. As these
different procedures may impact on EV type, number, integrity
and cargo (Taylor and Shah, 2015), a precise analysis of the bio-
chemical and biophysical characteristics of the isolates is required.
The International Society for Extracellular Vesicles (ISEV) provided
a combination of minimal experimental requirements needed to
properly deﬁne EV isolates in the different experimental
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within the isolates should combine two different techniques to
couple the measurement of the distribution size (using nano-
particle-tracking analysis (Nanosight), dynamic light scattering or
resistive pulse sensing) with single vesicle analysis based on mi-
croscopical techniques (such as electron microscopy, atomic force
microscopy or immunoﬂuorescence).
In addition, criteria for EV identiﬁcation include the assessment for
the presence of EV-associated proteins as well as absence of con-
taminant-associated proteins (Lötvall et al., 2014). Proteomic studies
identiﬁed various proteins expressed on EV membranes, which can be
used as EV markers (Table 1). They include tetraspanins (CD9, CD63
and CD81), Alix, Major Histocompatibility Complex (MHC) molecules
and cytosolic stress-related proteins (Heat Shock Proteins; HSPs),
Tsg101 and ESCRT-3 (Witwer et al., 2013). Although some of these
molecules were initially proposed as speciﬁc markers for exosomes,
such as CD9, CD63 and CD81, they were subsequently shown to be
present in apoptotic bodies and microvesicles as well (Crescitelli et al.,
2013). Therefore, at present, a speciﬁc marker for the distinction of EV
subtypes is lacking.
This notion was recently underlined by an extensive quantita-
tive proteomic analysis performed on human dendritic cell-de-
rived EVs (Kowal et al., 2016). In this study, it appeared that several
classically used exosome markers (MHC class I, Flotillin, HSPs 70-
kDa) were similarly present in all EV types. In addition, more se-
lective markers such as Syntenin-1, Metalloproteinase Domain-
Containing Protein 10 (ADAM-10) and Tsg101 were shown to be
associated with Tetraspanin-enriched small EVs, representing new
markers for exosomes (Kowal et al., 2016). This work provides
guidelines to deﬁne subtypes of EVs for future functional studies.
2.3. General content and mechanism of action
EVs are composed of membrane fragments, which encloses a
broad variety of bioactive lipids, cytoplasmic proteins and nucleic
acids (mRNAs, non-coding RNAs, miRNAs and other small RNAs)
(Witwer et al., 2013). In general, the content of EVs reﬂects that of
the cell of origin (Quesenberry et al., 2014). However, selected
molecules appear speciﬁcally enriched in EVs in respect to the
originating cell. The lipid content of EVs, for instance, appears
highly enriched in glycosphingolipids, sphingomyelin, cholesterol,
and phosphatidyl-serine (Llorente et al., 2013). Of interest, EV-
associated RNA is predominantly smaller in size than within the
cell fraction (Eirin et al., 2014). Indeed, RNA sequencing of urine or
serum-derived EVs indicated a predominance of small non coding
RNAs (Bellingham et al., 2012; Miranda et al., 2014). In addition,
speciﬁc miRNAs have been enriched in EVs of MSCs (Collino et al.,
2015). Possible mechanisms involving RNA packaging within EVs
have also been identiﬁed (Zaborowski et al., 2015). Among them, it
has been proposed that 3′ end post-transcriptional modiﬁcations
may drive miRNA sorting into EVs (Koppers-Lalic et al., 2014).
Extensive catalogues of proteins, lipids and RNAs in different
types of EVs are available in online databases: ExoCarta, EVpedia,
and Visiclepedia (Kalra et al., 2012; Keerthikumar et al., 2015; Kim
et al., 2015). In addition, EVs content may be inﬂuenced by phy-
sical or chemical stresses, including oxidative stress, hypoxia and
inﬂammation (Robbins and Morelli, 2014). Growth factor stimu-
lation of the originating cells may also inﬂuence the content and
functional properties of EVs. When adipose tissue derived stem
cells were treated with Platelet Derived Growth Factor (PDGF), an
increased pro-angiogenic activity of deriving EVs was observed
(Lopatina et al., 2014). This concept is relevant both for the pos-
sible use of EVs as marker of pathological conditions and as pos-
sible therapeutic option to ameliorate EV content.
EVs have the capacity to modify the activity of target cells using
different mechanisms, such as extracellular cell stimulationthrough surface receptor interactions and receptor transfer to the
target cell membrane (Cocucci et al., 2009). Alternatively, EVs can
modify target cells due to their membrane fusion or their en-
docytosis/phagocytosis, with subsequent release and transfer of
proteins and nucleic acids to target cell (Mathivanan et al., 2010).
In particular, mRNAs present in EVs can be transferred to recipient
cells and translated into functional proteins. Furthermore, also
miRNAs can be shuttled between cells and EVs leading to the re-
pression of speciﬁc mRNAs present in recipient cells (Collino et al.,
2015). Finally, non-coding RNA present inside EVs may have a role
in cell regulation. Therefore, among the possible mechanisms of
action, EV-mediated RNA horizontal transfer may be instrumental
for the reprogramming effect of target cells, as suggested in pio-
neering studies of the ﬁeld (Deregibus et al., 2007; Ratajczak and
Ratajczak, 2016).3. EVs in the nephron inter-cellular communication
3.1. Urinary EVs
Urine is a rich reservoir of EVs released by cells lining the nephron.
The contribution of plasma circulating EVs to the urinary pool appears
quite limited, as conﬁrmed by uEVs proteomic analysis showing that
uEVs are largely made up of exosomes derived from the tubular cell
apical plasma membrane (Pisitkun et al., 2004). In particular, the
majority of EVs released into the pre-urine appeared to derive from
the ﬁrst part of the nephron's cells, with a limited contribution of the
lower urinary collecting system (Pisitkun et al., 2004). However, a
minor contribution of sera EVs could be speculated and possibly in-
creased in condition of renal pathology. Indeed, a recent publication
reported that when labelled EVs were administered i.v., around 2.5% of
injected EVs were found in the urine (Oosthuyzen et al., 2016). In
general, uEVs are characterized by high expression of CD24 (Dimuccio
et al., 2014; Keller et al., 2007), a membrane glycoprotein able to in-
teract with various ligands, including adhesion molecules such as
P-selectin and L1 cell adhesion molecule (Ayre et al., 2016). The ex-
pression of speciﬁc podocyte markers, such as Podocin and Podoca-
lyxin, or tubular segment speciﬁc markers may sign the origin of the
uEVs from the different cells along the nephron (Salih et al., 2014). In
addition, normal urine contains EVs expressing CD133, a marker of
scattered CD133þ cells along the nephron. Alterations in the levels of
CD133þ EVs were reported in patients with end stage kidney disease
or transplanted patients with slow graft function suggesting that
CD133 may represent a marker of renal function and possibly reﬂect
the activity of CD133þ cells along the nephron (Dimuccio et al., 2014).
The number and content of uEVs may also vary during disease
(Zhou et al., 2006). In these terms, uEVs may reﬂect the physio-
pathological state of kidneys (Record et al., 2011). A number of
molecules (including mRNA, proteins and miRNAs) have been
identiﬁed as candidate markers for kidney injury (Ranghino et al.,
2015). Among the most promising markers, the podocyte marker
Wilms’ Tumour 1 (WT1) was successfully correlated to glomerular
damage and chronic injury whereas the Activating Transcription
Factor 3 and the Neutrophil Gelatinase-Associated Lipocalin ap-
peared to be early markers for detection of acute kidney injury
(Ranghino et al., 2015). Therefore, uEVs are highly studied as
markers of renal damage and repair. However, the detailed ana-
lysis of this aspect is beyond the scope of the review.
3.2. Functional effect of nephron cell-derived EVs
The unidirectional ﬂux of urine along the nephron likely sug-
gests that EVs from upper nephron segments could be uptaken by
distal cells. Indeed, both distal tubule and collecting duct cells
have the capacity to taken up EVs released by proximal tubule cells
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from the upper collecting duct were able to transfer Aquaporin-2
to the lower collecting duct cells, thereby increasing the water
ﬂow of recipient cells (Street et al., 2011). In contrast, in polycystic
kidney disease, EVs derived from proximal tubular cells mainly
interact with primary cilia of recipient cells increasing intracellular
calcium level (Hogan et al., 2009; Pocsfalvi et al., 2015). The hor-
monal mechanisms regulating the uptake of EVs in renal cells has
been highlighted in a recent work. In this paper, Desmopressin, a
Vasopressin analogue, selectively stimulated EV uptake selectively
in tubular cells in vitro and in parallel a Vasopressin antagonist
reduced the uptake of injected EVs within renal tissue in vivo
(Oosthuyzen et al., 2016).
In addition, preliminary data indicate a possible role of uEVs in
communication along the nephron. EVs from proximal tubular
cells cultured in presence of dopamine receptor agonist were able
to decrease radical production in distal tubular cells, indicating the
transfer of an anti-inﬂammatory message (Gildea et al., 2014).
Nephron cell-released EVs also appeared as a mechanism involved
in progression toward renal tissue maladaptive repair and ﬁbrosis
after damage. Tubular epithelial cell-derived EVs subjected to hy-
poxic damage in vitro studies were shown to induce ﬁbroblast
activation and proliferation, by the transfer of TGF-β1 mRNA
(Borges et al., 2013). This mechanism underlines the role of the
EVs in modulation of the microenvironment and in ampliﬁcation
of damage.
All together, these studies indicate the role of EVs in cell-to-cell
communication along the nephron during both physiological and
pathological conditions, even though the mechanisms are not
completely clear.4. Therapeutic effect of EVs derived from different sources of
stem/progenitor cells on kidney regeneration
4.1. Therapeutic effect of mesenchymal stromal cell-derived EVs
From a therapeutic point of view, EVs have been exploited for
their ability to act on different cell types and modulate relevant
cellular processes, such as proliferation (Zhan et al., 2015),Table 2
Effects of EVs of different origin in animal models of renal injury.
Cell sources of EVs In vivo models of renal injury Doses
BM-MSCs Glycerol-induced AKI 15 μg (by 7.5105
2.2108 EVs
IRI 30 μg
Cisplatin-induced AKI 100 μg
100 μg þ50 μg eve
Remnant kidney (CKD) 30 μg
Gentamicin-induced AKI 100 μg
CB-MSCs Cisplatin-induced AKI 200 μg
IRI 30 μg
WJ-MSCs IRI 100 μg
Kidney-MSCs IRI 2107 EVs
HLSC Glycerol-induced AKI 1.9109 Evs (by 3.5
5.5109 Evs (by 10
EPC IRI 30 μg
Thy1.1 glomerulonephritis 30 μg/100 g body w
Urine derived- MSCs Diabetic nephropathy 100 μg weekly
Embryonic-MSCs Remnant kidney and diet (CKD) 7 μg twice daily for
Fibroblast-EVs Glycerol-induced AKI 15 μg (by 7.5105
Thy1.1 glomerulonephritis 30 μg/100 g body w
EVs from different sources and different administration modality have been tested in mo
renal repair are reported. Abbreviations: AKI: acute kidney injury, CKD: chronic kidney
stem cells, IRI: ischemia reperfusion injury.angiogenesis (Gai et al., 2016; Merino-González et al., 2016) and
immune tolerance (Robbins and Morelli, 2014). The resulting ef-
fect, summarized as a general regenerative potential, has been
investigated in different experimental animal models of renal in-
jury mainly using mesenchymal stromal cells of different origin
(Table 2).
EVs derived from bone marrow mesenchymal stromal cells
(EV-MSCs) were the ﬁrst to be tested in vivo in models of acute
kidney injury (AKI). A single intravenous injection of EV-MSCs
during the peak of renal damage resulted in acceleration of mor-
phological and functional recovery of glycerol-induced AKI in SCID
mice (Bruno et al., 2009). The effect of EV-MSCs treatment was
comparable to that obtained with the cells of origin, indicating
that EVs might mimic the beneﬁcial effects of MSCs. In a different
model of ischemia and reperfusion injury (IRI), a single adminis-
tration of EV-MSCs immediately after damage protected rats from
AKI and prevented chronic kidney disease (CKD) development
(Gatti et al., 2011). EV-MSCs were also able to minimize genta-
micin-induced AKI in rats (Reis et al., 2012). In analogy, in the
lethal model of AKI induced by cisplatin, a single dose of EV-MSCs
improved the survival of SCID mice, but chronic tubular injury
developed in surviving mice. In this experimental model, multiple
doses of EV-MSCs, at different time points after cisplatin admin-
istration, were required to improve the survival of SCID mice and
to abolish the development of chronic tubular injury (Bruno et al.,
2009).
The need for multiple EV injections was not conﬁrmed in the
remnant kidney CKD mouse model (He et al., 2012). In this model
of 5/6 subtotal nephrectomy, a single EV-MSCs administration was
sufﬁcient to preserve the function of the remnant kidney, to pre-
vent tubular atrophy and interstitial lymphocyte inﬁltration, and
to limit renal ﬁbrosis.
The detailed effect of MSC-EVs was explored in in vitro ex-
periments on murine tubular renal cells. MSC-EVs prevented
apoptosis and promoted proliferation (Bruno et al., 2012, 2009).
The inhibition of in vitro apoptosis was associated with the down-
regulation of genes involved in the execution phase of cell apop-
tosis (Caspase 1 and 8) and with the up-regulation of anti-apop-
totic genes (Bcl-xL and Bcl2) (Bruno et al., 2012). In addition, in an
in vitro model of IRI (Lindoso et al., 2014), the survival effect ofTherapeutic effect Ref.
cells) Yes (Bruno et al., 2009)
(Collino et al., 2015)
(Gatti et al., 2011)
No (Bruno et al., 2012)
ry 4 days Yes
Yes (He et al., 2012)
Yes (Reis et al., 2012)
Yes (Zhou et al., 2013)
Yes (Ju et al., 2015)
Yes (Zou et al., 2014)
Yes (Choi et al., 2014)
105 cells) Yes (Herrera Sanchez et al., 2014)
105 cells)
Yes (Cantaluppi et al., 2012)
eight Yes (Cantaluppi et al., 2015)
Yes (Jiang et al., 2016)
4 consecutive days No (van Koppen et al., 2012)
cells) No (Bruno et al., 2009)
eight No (Cantaluppi et al., 2015)
dels of AKI and CKD. EV origin, experimental model and resulting effect in terms of
disease, BM: bone marrow, CB: cord blood; WJ: Wharton’s Jelly, HLSC: human liver
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miRNA transfer. In parallel, a transcriptional modulation of en-
dogenous miRNAs was observed within injured cells. Prediction of
miRNA targets showed that miRNAs modulated were involved in
downregulation of coding-mRNAs associated with apoptosis, cy-
toskeleton reorganization, and hypoxia.
Similar results showing induction of renal regeneration were also
obtained using MSCs from fetal tissues. EVs produced by human
Wharton's Jelly MSCs (WJ-MSCs) (Zou et al., 2014) and by umbilical
cord MSCs (UC-MSCs) (Ju et al., 2015) were able to reverse the mor-
phological and functional alteration in IRI rats, in both the acute and
chronic stage. Moreover, exosomes produced by human UC-MSCs
were able to repair cisplatin induced AKI in rats by ameliorating oxi-
dative stress, reducing cell apoptosis and promoting cell proliferation
(Zhou et al., 2013). At variance, no therapeutic effect was obtained
using EV-MSCs derived from human embryonic stem cells in a CKD
model (van Koppen et al., 2012). In this study, EV-MSCs were ad-
ministered twice daily for 4 consecutive days in rats with established
CKD induced by 5/6 nephrectomy combined with L-NG–nitroarginine
and 6% NaCl diet, using therefore a curative protocol (van Koppen
et al., 2012). This is the only paper, to our knowledge, where EVs were
used in an established model of CKD. At variance, in the other papers
in the ﬁeld, EVs were injected soon after injury to prevent develop-
ment of CKD in a preventive approach (Gatti et al., 2011; Ju et al., 2015;
Zou et al., 2014).
Finally, MSCs resident in adult tissue different from bone
marrow, such as kidney and liver were also investigated as pos-
sible sources of EVs to obtain acceleration of renal repair. Ad-
ministration of EVs derived from kidney MSCs into mice with AKI
induced by IRI, signiﬁcant improved renal function and morphol-
ogy, also inducing an amelioration of microvascular rarefaction by
pro-proliferative and anti-apoptotic effects on tubular and en-
dothelial cells (Choi et al., 2014). Similarly, puriﬁed EVs derived
from human liver stem cells ameliorated renal function and mor-
phology in a manner comparable to the HLSCs themselves, in an
experimental AKI model induced by glycerol administration
(Herrera Sanchez et al., 2014).
4.2. Other sources of EVs for kidney repair
Human endothelial progenitors cells (EPCs), a source of potent
pro-angiogenic circulating progenitors obtained from peripheral
blood of healthy donors, have been explored as possible EV source
of for kidney regeneration. In a rat model of IRI, i.v. administration
of EPCs-derived EVs (EV-EPCs) immediately after IRI prevented the
renal functional damage (Cantaluppi et al., 2012). In particular, EV-
EPCs conferred functional and morphologic protection from AKI by
enhancing tubular cell proliferation and reducing apoptosis and
leukocyte inﬁltration (Cantaluppi et al., 2012). In the same model,
EV-EPCs also protected against progression of CKD after IRI by
inhibiting capillary rarefaction, glomerulosclerosis, and tubule-
interstitial ﬁbrosis (Cantaluppi et al., 2012). Moreover, EV-EPCs
were tested in the experimental anti-Thy1.1 glomerulonephritis in
rats induced by complement-mediated mesangial injury. After i.v.
injection in Thy1.1-treated rats, EV-EPCs inhibited mesangial cell
activation, leukocyte inﬁltration and apoptosis, decreased protei-
nuria, increased serum complement haemolytic activity and
ameliorated renal function (Cantaluppi et al., 2015).
Recently, EVs obtained by multipotent human urine derived
MSCs were tested in a rat model of streptozotocin-induced dia-
betic nephropathy. Weekly repeated intravenous injections of this
type of EVs could potentially reduce the urine volume and urinary
microalbumin excretion, prevent podocyte and tubular epithelial
cell apoptosis, suppress the Caspase-3 overexpression and increase
glomerular endothelial cell proliferation in diabetic rats (Jiang
et al., 2016).Although different sources of EVs depicted above seem to dis-
play a similar protecting effect on acute kidney damage and to
protect from its progression toward ﬁbrosis, the effect cannot be
ascribed to a general mechanisms. Indeed, ﬁbroblasts-derived EVs,
used as control cell source for EV generation did not ameliorate
renal function (Bruno et al., 2012, 2009; Cantaluppi et al., 2015),
indicating a speciﬁc action of EVs derived from stem cell types. At
variance, the protective effect of stem cell-derived EVs in CKD
models appears to be conﬁrmed, on the light of negative results
obtained using a single (Bruno et al., 2012) or even multiple ad-
ministrations (van Koppen et al., 2012). Doses, number and timing
of administration still require further investigation.5. Mechanisms of action of EVs in kidney regeneration
5.1. EV uptake and bio-distribution
As depicted in the paragraphs above, EVs from different stem
cell sources triggered in vitro and in vivo pro-proliferative and anti-
apoptotic events. Among the possible mechanisms of action, it
appears that the entrance of EV-MSCs into target cells is the ﬁrst
requirement for the biological effects in vitro. EV-MSCs expressed
several adhesion molecules typically expressed by the originating
MSCs (CD44, α-1, α-4 and α-5 integrins). CD44 and α-1 integrin
were involved in EV internalization into renal tubular epithelial
and treatment with speciﬁc blocking antibodies prevented EV-
MSCs incorporation into target cells (Bruno et al., 2009; Lindoso
et al., 2014). In addition, Annexin V was instrumental in EV-MSCs
incorporation, since pre-treatment of EVs with Annexin V abro-
gated their uptake and effects on target cells (Iglesias et al., 2012).
In vivo evidences conﬁrm the requirement of mechanisms of
organ targeting and cell entrance for EV regenerative effects.
In fact, pre-treatment of EVs with trypsin, that damages the pro-
teins on the surface necessary for EV homing and uptake into
target cells, abolished their in vivo regenerative capacity. Im-
munoﬂuorescence experiments indicated that, after injection in
mice with glycerol- or IRI-induced AKI, EV-MSCs and EV-EPCs lo-
calized within peritubular capillaries and tubules, as soon as 1 h
after injection, with a peak of accumulation at 6 h after adminis-
tration (Bruno et al., 2009; Cantaluppi et al., 2012; Gatti et al.,
2011). In analogy, labelled EV-MSCs localized within the renal
tissue in an AKI model were rapidly detected using optical imaging
technique (Grange et al., 2014). Of interest, normal control mice
without AKI showed absence of EV localization within kidneys.
Minimal renal localization of i.v. injected EVs was conﬁrmed by a
study performing a detailed organ bio-distribution in a healthy
animal using ﬂuorescence intravital imaging (Wiklander et al.,
2015). These data suggest that increased vascular permeability and
tissue damage, or possibly expression of speciﬁc cell receptors for
EV entrance, are required for EV renal localization in renal pa-
thology. At variance, 60 and 120 min after i.v. administration, EVs
were detected within the renal tissue using a sensible biolumi-
nescent EV membrane reporter, suggesting that a small amount of
EVs are cleared in physiological condition via the renal route (Lai
et al., 2014).
5.2. Molecular mechanisms of EV activity
As reported above, EVs are enriched in small non-coding RNA
species. The mRNA and miRNA content of therapeutic MSC-EVs
has been characterized by microarray and RNA sequencing ap-
proaches by several investigations (Bruno et al., 2009; Collino
et al., 2015, 2010). In particular, MSC-EVs were reported to contain
mRNAs of genes involved in the control of transcription (Tran-
scription Factor CP2, Clock Homolog, etc.), cell proliferation (RBL1,
S. Bruno et al. / European Journal of Pharmacology 790 (2016) 83–9188SUMO-1, etc.) and immune-regulation (Bruno et al., 2009). Se-
quencing of miRNAs in MSCs and EPCs-derived EVs similarly
showed the presence of miRNAs involved in the control of a
number of cellular processes (e.g. proliferation, angiogenesis,
apoptosis, cell adhesion, inﬂammation) (Cantaluppi et al., 2012;
Collino et al., 2010). Moreover, the miRNAs present in the EV-MSCs
are functionally active and able to induce the down-regulation of
speciﬁc targeted proteins (Bcl-2, cyclin D1 and PTEN) in the re-
cipient cells (Collino et al., 2015).
Several studies identiﬁed the transfer of extracellular RNA as
the main mechanism for the EV therapeutic effects (György et al.,
2011). When EVs of different origin were incubated with RNase,
the in vitro and in vivo effects were blunted, indicating that re-
generative properties were mediated by RNA species carried by
EVs (Bruno et al., 2012, 2009; Cantaluppi et al., 2012; Ju et al.,
2015; Reis et al., 2012). The transfer of speciﬁc mRNA and its
subsequent translation into proteins in renal tubular cells has been
shown both in vitro and in vivo (Bruno et al., 2009; Ju et al., 2015).
The mechanisms of endogenous renal tissue repair after AKI in-
clude dedifferentiation of surviving cells followed by proliferation
to repopulate the damaged tubules (Bonventre, 2003). In this
context, in vivo and in vitro experiments indicated that mRNA for
human Hepatocyte Growth Factor (HGF), a potent factor for tub-
ular repair and regeneration, was contained in UC-MSCs-derived
EVs and delivered into damaged tubular cells to be translated into
protein. In addition, the induction of endogenous rat HGF mRNA
and protein synthesis was also observed (Ju et al., 2015). Moreover,
in vitro studies indicated that transfer of the Insulin Growth Factor
1 (IGF-1) receptor mRNA to renal tubular cells through MSC-EVs
potentiated tubular sensitivity to locally produced IGF-1, increas-
ing cell proliferation (Tomasoni et al., 2013). Therefore, trafﬁcking
mRNAs from speciﬁc growth factors and their receptors could have
an important role in the regenerative effect exerted by EVs in
different experimental renal injury models. In addition, stem cell
derived EVs may contain mRNAs coding for anti-apoptotic mole-
cules and for complement inhibitors such as Factor H, CD55 and
CD59, and the related proteins. In vitro experiments indicated that
EV-EPCs transferred to mesangial cell mRNAs coding for Factor H,
CD55 and CD59 and inhibited anti-Thy1.1 antibody/complement-
induced apoptosis and C5b-9/C3 mesangial cell deposition (Can-
taluppi et al., 2012).
The pivotal role of miRNAs in the renoprotective effect of EVs
was clearly proved by its abrogation after nonspeciﬁc miRNA de-
pletion by Dicer or Drosha knock-down in the progenitor/stem
cells (Cantaluppi et al., 2012; Collino et al., 2015). In addition,
depletion of speciﬁc miRNAs in EPCs-derived EVs showed the role
of the pro-angiogenic miRNA-126 and miRNA-296 (Cantaluppi
et al., 2012). These results indicate that EVs derived from EPCs and
BM-MSCs improve kidney injuries by delivering their miRNA cargo
that contributes to a reprogramming of damaged resident renal
cells to a regenerative program.
Extensive proteomic analysis has been performed on EV-MSCs
(Kim et al., 2012). EV-MSCs contain proteins that are characteristic
of MSCs (e.g. CD29, CD73, CD44 and CD105), proteins associated
with intra-cellular EV biogenesis and trafﬁcking (RAB protein fa-
mily) and proteins associated with self-renewal and differentiation
processes (TGF-β, MAPK, PPAR, etc.). Gene ontology analyses of
such proteins indicated that several biological processes are re-
presented, including vesicle-mediated transport, cell cycle and
proliferation, cell migration, morphogenesis and developmental
processes. In addition, EVs derived from urine MSCs contained
speciﬁc growth factors, such as Vascular Endothelial Growth Fac-
tor, Transforming Growth Factor α1, Angiogenin and Bone Mor-
phogenetic Protein 4, that are known to be podocyte survival
factors and could be implicated in renal protection in diabetes
(Jiang et al., 2016).A different possible activity of EVs is the transfer of wildtype
proteins to reprogram mutant cells. This activity has been de-
monstrated for EVs derived from MSCs and amniotic ﬂuid-derived
stem cells, that were able to shuttle a cysteine-selective transport
channel (cystinosin) that restored function in mutant tubular tar-
get cells (Iglesias et al., 2012). This opens new perspectives for
possible therapeutic applications of EVs in genetic-based diseases.6. Pharmacological application of EVs
6.1. Limits and beneﬁts of EV therapy
The therapeutic effect of EVs in renal regenerative medicine is
promising and supported by a number of preclinical studies.
However, comparison of results from these studies is limited by a
number of reasons. First, different techniques of EV isolation have
been used as well as different cell culture conditions of the ori-
ginating cells that may account for different EV nature or content.
Moreover, standardization of the dose of EV administered is still
lacking. Several studies quantiﬁed EV protein content, that in turn
may also be inﬂuenced by contaminants such as serum or bovine
albumin in the culture medium. Others studies used EVs released
by a deﬁned cell number, and most recently the count of the EV
number to be administered appears as the most reliable method
(Table 2). However, even in this last case, the use of different in-
struments of quantiﬁcation, based on different technology, may
lead to incomparable results.
In addition, different problems may limit the clinical use of EVs.
EVs can be classiﬁed as biological medicinal products, and their
production needs to follow the guidelines on biological active
substances of the different countries. First of all, criteria for scal-
able and reliable EV isolation methods and the best storage con-
ditions for long term preservation of EV functions, compatible
with current good manufacturing practice are required (Taylor and
Shah, 2015). In addition, the mechanism of action of EVs including
the characterization of the active substances is fundamental for a
clinical application. Indeed, the pharmaceutical classiﬁcation and
approval by the National Agencies for Drug Regulation strictly
depends on the identiﬁcation of the active and ancillary compo-
nents of EVs. A detailed analysis of the criteria for the use of EVs in
clinical trials is provided in a statement paper of the ISEV society
(Lener et al., 2015). As EV preparations represent a homogenous
EV collection, information on possible differential effect of speciﬁc
EV subtypes could provide a better standardization of EVs. Finally,
although stem cell derived EVs such as MSC-EVs may possess
immune-modulating activity, (Bruno et al., 2015) immune related
problems of EV administration may be present, especially asso-
ciated with multiple administrations.
On the other side, a number of beneﬁts associate with EV-based
therapy and support an active research in the ﬁeld to improve the
knowledge on EV content and mechanisms of action. The ﬁrst
beneﬁt of EV therapy obviously derives from the comparison with
the use of the cell source from which they originate. Having a si-
milar therapeutic efﬁcacy, EV therapy is devoid of issues related to
ectopic engraftment or tissue formation, maldifferentiation or
occlusion of the pulmonary artery that certainly concern the use of
cell therapies. Second, characterization of EV cargo in terms of
RNAs and proteins appears feasible and more applicable than that
of cell therapy. In particular, EVs offer the possibility to use criteria
based not only on phenotypic characterization but also on func-
tional assays. The deﬁnition of a “therapeutic proﬁle” based on the
expression of genes required for the therapeutic effect of EVs
would ameliorate the safety and possibly the result of EV
administration.
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Preliminary application of EV therapy has been proposed to
exploit the EV immune-modulating and anti-tumour activity. EV-
MSCs have been ﬁrst administered for compassion use in a patient
with steroid refractory graft versus host disease (Kordelas et al.,
2014). Multiple injections (every 2–3 days) of EVs obtained from
MSCs of unrelated bone marrow donors showed anti-in-
ﬂammatory effects and ameliorated the clinical symptoms of the
patient without adverse effects, indicating the safeness of EV ad-
ministration. Three phase 1 clinical immunotherapy trials report-
ing feasibility and safety of autologous EV therapeutics have also
been published (Escudier et al., 2005). Nevertheless, the ﬁrst trial
on MSC-derived Microvesicles and Exosomes on β-cell Mass in
Type I Diabetes Mellitus is now enrolling (NCT02138331, www.
clinicaltrial.gov). A possible advance in the use of EV based
therapies can be envisaged by the use of vegetable EVs which
appear as an edible, safe source of nanovectors (Quesenberry et al.,
2015). In particular, two trials are currently being conducted using
grapefruit-derived exosome-like nanoparticles. In these trials,
plant-derived EVs, loaded with drugs, are orally administered for
cancer treatment (Wang et al., 2013).
6.3. EV engineering
EVs may also be envisaged as drug carriers, as their surface
composition leading to cell speciﬁc mechanisms of internalization
may be coupled with addition of desired drugs. As discussed
above, integrin- or tetraspanin-adhesion molecule complexes are
involved in speciﬁc cellular uptake of EVs (Lindoso et al., 2014).
Indeed, in comparison with liposomes, EVs are considered to
display an increased half life and reduced uptake by the reticulo-
endothelial system due to presence of an autologous surface mo-
lecules system (Johnsen et al., 2014). EVs may be modiﬁed for
loading of drugs, as shown for the lipophilic drugs Doxorubicine or
Curcumine which, being able to spontaneously enter the EVs,
concentrate in their inside (Sun et al., 2010; Tian et al., 2014). In
these studies, drug-loaded EVs showed an increased efﬁcacy in
term of anti-tumour or anti-inﬂammatory activity as compared to
the drug alone. Another possible approach is the EV enrichment
with therapeutic miRNAs (Johnsen et al., 2014). Finally, surface
peptides might also be added to increase the speciﬁcity of the
delivery. Although none of these approaches has been applied in
renal preclinical models, it appears an interesting possibility.7. Conclusions
In conclusion, EVs appear an interesting pharmacological tool
for renal regenerative medicine. In particular, EVs derived from
MSCs of a number of different sources has been proven to ame-
liorate renal function in AKI models. The application of EV based
therapy for CKD is at variance less established. In particular, the
deﬁnition of the therapeutic doses of EVs, standardization of EV
quantiﬁcation, modalities of administration and the best timing to
start the treatment are still required. From all these studies, it can
be prospected that the identiﬁcation of the mechanisms of action
of EVs and of the renoprotective molecules involved may allow the
generation of modiﬁed, enriched EVs or engineered EVs for re-
generative renal applications.References
Akers, J.C., Gonda, D., Kim, R., Carter, B.S., Chen, C.C., 2013. Biogenesis of extra-
cellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, andapoptotic bodies. J. Neurooncol. 113, 1–11. http://dx.doi.org/10.1007/
s11060-013-1084-8.
Aliotta, J.M., Pereira, M., Wen, S., Dooner, M.S., Del Tatto, M., Papa, E., Goldberg, L.R.,
Baird, G.L., Ventetuolo, C.E., Quesenberry, P.J., Klinger, J.R., 2016. Exosomes in-
duce and reverse monocrotaline-induced pulmonary hypertension in mice.
Cardiovasc. Res. . http://dx.doi.org/10.1093/cvr/cvw054
Al-Nedawi, K., Meehan, B., Kerbel, R.S., Allison, A.C., Rak, J., 2009. Endothelial ex-
pression of autocrine VEGF upon the uptake of tumor-derived microvesicles
containing oncogenic EGFR. Proc. Natl. Acad. Sci. USA 106, 3794–3799. http:
//dx.doi.org/10.1073/pnas.0804543106.
Ayre, D.C., Pallegar, N.K., Fairbridge, N.A., Canuti, M., Lang, A.S., Christian, S.L., 2016.
Analysis of the structure, evolution, and expression of CD24, an important
regulator of cell fate. Gene . http://dx.doi.org/10.1016/j.gene.2016.05.038.
Baietti, M.F., Zhang, Z., Mortier, E., Melchior, A., Degeest, G., Geeraerts, A., Ivarsson,
Y., Depoortere, F., Coomans, C., Vermeiren, E., Zimmermann, P., David, G., 2012.
Syndecan-syntenin-ALIX regulates the biogenesis of exosomes. Nat. Cell Biol.
14, 677–685. http://dx.doi.org/10.1038/ncb2502.
Baj-Krzyworzeka, M., Szatanek, R., Weglarczyk, K., Baran, J., Urbanowicz, B., Brański,
P., Ratajczak, M.Z., Zembala, M., 2006. Tumour-derived microvesicles carry
several surface determinants and mRNA of tumour cells and transfer some of
these determinants to monocytes. Cancer Immunol. Immunother. 55, 808–818.
http://dx.doi.org/10.1007/s00262-005-0075-9.
Bellingham, S.A., Guo, B.B., Coleman, B.M., Hill, A.F., 2012. Exosomes: vehicles for
the transfer of toxic proteins associated with neurodegeneration disorder?
Front. Physiol. 3, 124. http://dx.doi.org/10.3389/fphys.2012.00124.
Bonventre, J.V., 2003. Dedifferentiation and proliferation of surviving epithelial
cells in acute renal failure. J. Am. Soc. Nephrol. 14 (Suppl 1), S55–S61.
Borges, F.T., Melo, S.A., Özdemir, B.C., Kato, N., Revuelta, I., Miller, C.A., Gattone, V.H.,
LeBleu, V.S., Kalluri, R., 2013. TGF-β1-containing exosomes from injured epi-
thelial cells activate ﬁbroblasts to initiate tissue regenerative responses and
ﬁbrosis. J. Am. Soc. Nephrol. 24, 385–392. http://dx.doi.org/10.1681/
ASN.2012101031.
Bruno, S., Camussi, G., 2013. Role of mesenchymal stem cell-derived microvesicles
in tissue repair. Pediatr. Nephrol. 28, 2249–2254. http://dx.doi.org/10.1007/
s00467-013-2413-z.
Bruno, S., Deregibus, M.C., Camussi, G., 2015. The secretome of mesenchymal
stromal cells: role of extracellular vesicles in immunomodulation. Immunol.
Lett. 168, 154–158. http://dx.doi.org/10.1016/j.imlet.2015.06.007.
Bruno, S., Grange, C., Collino, F., Deregibus, M.C., Cantaluppi, V., Biancone, L., Tetta,
C., Camussi, G., 2012. Microvesicles derived from mesenchymal stem cells en-
hance survival in a lethal model of acute kidney injury. PLoS One 7, e33115.
http://dx.doi.org/10.1371/journal.pone.0033115.
Bruno, S., Grange, C., Deregibus, M.C., Calogero, R.A., Saviozzi, S., Collino, F., Mor-
ando, L., Busca, A., Falda, M., Bussolati, B., Tetta, C., Camussi, G., 2009. Me-
senchymal stem cell-derived microvesicles protect against acute tubular injury.
J. Am. Soc. Nephrol. 20, 1053–1067. http://dx.doi.org/10.1681/ASN.2008070798.
Cantaluppi, V., Gatti, S., Medica, D., Figliolini, F., Bruno, S., Deregibus, M.C., Sordi, A.,
Biancone, L., Tetta, C., Camussi, G., 2012. Microvesicles derived from endothelial
progenitor cells protect the kidney from ischemia-reperfusion injury by mi-
croRNA-dependent reprogramming of resident renal cells. Kidney Int. 82,
412–427. http://dx.doi.org/10.1038/ki.2012.105.
Cantaluppi, V., Medica, D., Mannari, C., Stiaccini, G., Figliolini, F., Dellepiane, S.,
Quercia, A.D., Migliori, M., Panichi, V., Giovannini, L., Bruno, S., Tetta, C., Bian-
cone, L., Camussi, G., 2015. Endothelial progenitor cell-derived extracellular
vesicles protect from complement-mediated mesangial injury in experimental
anti-Thy1.1 glomerulonephritis. Nephrol. Dial. Transpl. 30, 410–422. http://dx.
doi.org/10.1093/ndt/gfu364.
Chavez-Muñoz, C., Morse, J., Kilani, R., Ghahary, A., 2008. Primary human kerati-
nocytes externalize stratiﬁn protein via exosomes. J. Cell. Biochem. 104,
2165–2173. http://dx.doi.org/10.1002/jcb.21774.
Choi, H.Y., Moon, S.J., Ratliff, B.B., Ahn, S.H., Jung, A., Lee, M., Lee, S., Lim, B.J., Kim, B.
S., Plotkin, M.D., Ha, S.K., Park, H.C., 2014. Microparticles from kidney-derived
mesenchymal stem cells act as carriers of proangiogenic signals and contribute
to recovery from acute kidney injury. PLoS One 9, e87853. http://dx.doi.org/
10.1371/journal.pone.0087853.
Cocucci, E., Racchetti, G., Meldolesi, J., 2009. Shedding microvesicles: artefacts no
more. Trends Cell Biol. 19, 43–51. http://dx.doi.org/10.1016/j.tcb.2008.11.003.
Collino, F., Bruno, S., Incarnato, D., Dettori, D., Neri, F., Provero, P., Pomatto, M.,
Oliviero, S., Tetta, C., Quesenberry, P.J., Camussi, G., 2015. AKI recovery induced
by mesenchymal stromal cell-derived extracellular vesicles carrying micro-
RNAs. J. Am. Soc. Nephrol. 26, 2349–2360. http://dx.doi.org/10.1681/
ASN.2014070710.
Collino, F., Deregibus, M.C., Bruno, S., Sterpone, L., Aghemo, G., Viltono, L., Tetta, C.,
Camussi, G., 2010. Microvesicles derived from adult human bone marrow and
tissue speciﬁc mesenchymal stem cells shuttle selected pattern of miRNAs.
PLoS One 5, e11803. http://dx.doi.org/10.1371/journal.pone.0011803.
Crescitelli, R., Lässer, C., Szabó, T.G., Kittel, A., Eldh, M., Dianzani, I., Buzás, E.I.,
Lötvall, J., 2013. Distinct RNA proﬁles in subpopulations of extracellular ve-
sicles: apoptotic bodies, microvesicles and exosomes. J. Extracell. Vesicles, 2.
http://dx.doi.org/10.3402/jev.v2i0.20677.
Deregibus, M.C., Cantaluppi, V., Calogero, R., Lo Iacono, M., Tetta, C., Biancone, L.,
Bruno, S., Bussolati, B., Camussi, G., 2007. Endothelial progenitor cell derived
microvesicles activate an angiogenic program in endothelial cells by a hor-
izontal transfer of mRNA. Blood 110, 2440–2448. http://dx.doi.org/10.1182/
blood-2007-03-078709.
Dimuccio, V., Ranghino, A., Praticò Barbato, L., Fop, F., Biancone, L., Camussi, G.,
S. Bruno et al. / European Journal of Pharmacology 790 (2016) 83–9190Bussolati, B., 2014. Urinary CD133þ extracellular vesicles are decreased in
kidney transplanted patients with slow graft function and vascular damage.
PLoS One 9, e104490. http://dx.doi.org/10.1371/journal.pone.0104490.
Eirin, A., Riester, S.M., Zhu, X.-Y., Tang, H., Evans, J.M., O’Brien, D., van Wijnen, A.J.,
Lerman, L.O., 2014. MicroRNA and mRNA cargo of extracellular vesicles from
porcine adipose tissue-derived mesenchymal stem cells. Gene 551, 55–64. http:
//dx.doi.org/10.1016/j.gene.2014.08.041.
EL Andaloussi, S., Mäger, I., Breakeﬁeld, X.O., Wood, M.J.A., 2013. Extracellular ve-
sicles: biology and emerging therapeutic opportunities. Nat. Rev. Drug Discov.
12, 347–357. http://dx.doi.org/10.1038/nrd3978.
Emmanouilidou, E., Melachroinou, K., Roumeliotis, T., Garbis, S.D., Ntzouni, M.,
Margaritis, L.H., Stefanis, L., Vekrellis, K., 2010. Cell-produced alpha-synuclein is
secreted in a calcium-dependent manner by exosomes and impacts neuronal
survival. J. Neurosci. 30, 6838–6851. http://dx.doi.org/10.1523/
JNEUROSCI.5699-09.2010.
Escudier, B., Dorval, T., Chaput, N., André, F., Caby, M.-P., Novault, S., Flament, C.,
Leboulaire, C., Borg, C., Amigorena, S., Boccaccio, C., Bonnerot, C., Dhellin, O.,
Movassagh, M., Piperno, S., Robert, C., Serra, V., Valente, N., Le Pecq, J.-B., Spatz,
A., Lantz, O., Tursz, T., Angevin, E., Zitvogel, L., 2005. Vaccination of metastatic
melanoma patients with autologous dendritic cell (DC) derived-exosomes: re-
sults of the ﬁrst phase I clinical trial. J. Transl. Med. 3, 10. http://dx.doi.org/
10.1186/1479-5876-3-10.
Gai, C., Carpanetto, A., Deregibus, M.C., Camussi, G., 2016. Extracellular vesicle-
mediated modulation of angiogenesis. Histol. Histopathol. 31, 379–391. http:
//dx.doi.org/10.14670/HH-11-708.
Gatti, S., Bruno, S., Deregibus, M.C., Sordi, A., Cantaluppi, V., Tetta, C., Camussi, G.,
2011. Microvesicles derived from human adult mesenchymal stem cells protect
against ischaemia-reperfusion-induced acute and chronic kidney injury. Ne-
phrol. Dial. Transpl. 26, 1474–1483. http://dx.doi.org/10.1093/ndt/gfr015.
Gildea, J.J., Seaton, J.E., Victor, K.G., Reyes, C.M., Bigler Wang, D., Pettigrew, A.C.,
Courtner, C.E., Shah, N., Tran, H.T., Van Sciver, R.E., Carlson, J.M., Felder, R.A.,
2014. Exosomal transfer from human renal proximal tubule cells to distal tu-
bule and collecting duct cells. Clin. Biochem. 47, 89–94. http://dx.doi.org/
10.1016/j.clinbiochem.2014.06.018.
Grange, C., Tapparo, M., Bruno, S., Chatterjee, D., Quesenberry, P.J., Tetta, C., Camussi,
G., 2014. Biodistribution of mesenchymal stem cell-derived extracellular ve-
sicles in a model of acute kidney injury monitored by optical imaging. Int. J.
Mol. Med. 33, 1055–1063. http://dx.doi.org/10.3892/ijmm.2014.1663.
Greening, D.W., Xu, R., Ji, H., Tauro, B.J., Simpson, R.J., 2015. A protocol for exosome
isolation and characterization: evaluation of ultracentrifugation, density-gra-
dient separation, and immunoafﬁnity capture methods. Methods Mol. Biol.
1295, 179–209. http://dx.doi.org/10.1007/978-1-4939–2550-6_15.
György, B., Szabó, T.G., Pásztói, M., Pál, Z., Misják, P., Aradi, B., László, V., Pállinger, E.,
Pap, E., Kittel, A., Nagy, G., Falus, A., Buzás, E.I., 2011. Membrane vesicles, cur-
rent state-of-the-art: emerging role of extracellular vesicles. Cell. Mol. Life Sci.
68, 2667–2688. http://dx.doi.org/10.1007/s00018-011-0689-3.
He, J., Wang, Y., Sun, S., Yu, M., Wang, C., Pei, X., Zhu, B., Wu, J., Zhao, W., 2012. Bone
marrow stem cells-derived microvesicles protect against renal injury in the
mouse remnant kidney model. Nephrology (Carlton) 17, 493–500. http://dx.doi.
org/10.1111/j.1440–1797.2012.01589.x.
Herrera Sanchez, M.B., Bruno, S., Grange, C., Tapparo, M., Cantaluppi, V., Tetta, C.,
Camussi, G., 2014. Human liver stem cells and derived extracellular vesicles
improve recovery in a murine model of acute kidney injury. Stem Cell Res. Ther.
5, 124. http://dx.doi.org/10.1186/scrt514.
Hogan, M.C., Manganelli, L., Woollard, J.R., Masyuk, A.I., Masyuk, T.V., Tammachote,
R., Huang, B.Q., Leontovich, A.A., Beito, T.G., Madden, B.J., Charlesworth, M.C.,
Torres, V.E., LaRusso, N.F., Harris, P.C., Ward, C.J., 2009. Characterization of PKD
protein-positive exosome-like vesicles. J. Am. Soc. Nephrol. 20, 278–288. http:
//dx.doi.org/10.1681/ASN.2008060564.
Iglesias, D.M., El-Kares, R., Taranta, A., Bellomo, F., Emma, F., Besouw, M., Levtch-
enko, E., Toelen, J., van den Heuvel, L., Chu, L., Zhao, J., Young, Y.K., Eliopoulos,
N., Goodyer, P., 2012. Stem cell microvesicles transfer cystinosin to human cy-
stinotic cells and reduce cystine accumulation in vitro. PLoS One 7, e42840.
http://dx.doi.org/10.1371/journal.pone.0042840.
Jiang, Z.-Z., Liu, Y.-M., Niu, X., Yin, J.-Y., Hu, B., Guo, S.-C., Fan, Y., Wang, Y., Wang, N.-
S., 2016. Exosomes secreted by human urine-derived stem cells could prevent
kidney complications from type I diabetes in rats. Stem Cell Res. Ther. 7, 24.
http://dx.doi.org/10.1186/s13287-016-0287-2.
Johnsen, K.B., Gudbergsson, J.M., Skov, M.N., Pilgaard, L., Moos, T., Duroux, M., 2014.
A comprehensive overview of exosomes as drug delivery vehicles - endogenous
nanocarriers for targeted cancer therapy. Biochim. Biophys. Acta 1846, 75–87.
http://dx.doi.org/10.1016/j.bbcan.2014.04.005.
Ju, G., Cheng, J., Zhong, L., Wu, S., Zou, X., Zhang, G., Gu, D., Miao, S., Zhu, Y., Sun, J.,
Du, T., 2015. Microvesicles derived from human umbilical cord mesenchymal
stem cells facilitate tubular epithelial cell dedifferentiation and growth via
hepatocyte growth factor induction. PLoS One 10, e0121534. http://dx.doi.org/
10.1371/journal.pone.0121534.
Kalra, H., Simpson, R.J., Ji, H., Aikawa, E., Altevogt, P., Askenase, P., Bond, V.C., Borràs,
F.E., Breakeﬁeld, X., Budnik, V., Buzas, E., Camussi, G., Clayton, A., Cocucci, E.,
Falcon-Perez, J.M., Gabrielsson, S., Gho, Y.S., Gupta, D., Harsha, H.C., Hendrix, A.,
Hill, A.F., Inal, J.M., Jenster, G., Krämer-Albers, E.-M., Lim, S.K., Llorente, A.,
Lötvall, J., Marcilla, A., Mincheva-Nilsson, L., Nazarenko, I., Nieuwland, R., Nolte-
’t Hoen, E.N.M., Pandey, A., Patel, T., Piper, M.G., Pluchino, S., Prasad, T.S.K.,
Rajendran, L., Raposo, G., Record, M., Reid, G.E., Sánchez-Madrid, F., Schiffelers,
R.M., Siljander, P., Stensballe, A., Stoorvogel, W., Taylor, D., Thery, C., Valadi, H.,
van Balkom, B.W.M., Vázquez, J., Vidal, M., Wauben, M.H.M., Yáñez-Mó, M.,Zoeller, M., Mathivanan, S., 2012. Vesiclepedia: a compendium for extracellular
vesicles with continuous community annotation. PLoS Biol. 10, e1001450. http:
//dx.doi.org/10.1371/journal.pbio.1001450.
Katsuda, T., Kosaka, N., Takeshita, F., Ochiya, T., 2013. The therapeutic potential of
mesenchymal stem cell-derived extracellular vesicles. Proteomics 13,
1637–1653. http://dx.doi.org/10.1002/pmic.201200373.
Keerthikumar, S., Chisanga, D., Ariyaratne, D., Al Saffar, H., Anand, S., Zhao, K., Sa-
muel, M., Pathan, M., Jois, M., Chilamkurti, N., Gangoda, L., Mathivanan, S., 2015.
ExoCarta: a web-based compendium of exosomal cargo. J. Mol. Biol. 428,
688–692. http://dx.doi.org/10.1016/j.jmb.2015.09.019.
Keller, S., Ridinger, J., Rupp, A.-K., Janssen, J.W.G., Altevogt, P., 2011. Body ﬂuid
derived exosomes as a novel template for clinical diagnostics. J. Transl. MEd. 9,
86. http://dx.doi.org/10.1186/1479–5876-9-86.
Keller, S., Rupp, C., Stoeck, A., Runz, S., Fogel, M., Lugert, S., Hager, H.-D., Abdel-
Bakky, M.S., Gutwein, P., Altevogt, P., 2007. CD24 is a marker of exosomes se-
creted into urine and amniotic ﬂuid. Kidney Int. 72, 1095–1102. http://dx.doi.
org/10.1038/sj.ki.5002486.
Kim, D.-K., Lee, J., Kim, S.R., Choi, D.-S., Yoon, Y.J., Kim, J.H., Go, G., Nhung, D., Hong,
K., Jang, S.C., Kim, S.-H., Park, K.-S., Kim, O.Y., Park, H.T., Seo, J.H., Aikawa, E., Baj-
Krzyworzeka, M., van Balkom, B.W.M., Belting, M., Blanc, L., Bond, V., Bongio-
vanni, A., Borràs, F.E., Buée, L., Buzás, E.I., Cheng, L., Clayton, A., Cocucci, E., Dela
Cruz, C.S., Desiderio, D.M., Di Vizio, D., Ekström, K., Falcon-Perez, J.M., Gardiner,
C., Giebel, B., Greening, D.W., Gross, J.C., Gupta, D., Hendrix, A., Hill, A.F., Hill, M.
M., Nolte-’t Hoen, E., Hwang, D.W., Inal, J., Jagannadham V., M., Jayachandran,
M., Jee, Y.-K., Jørgensen, M., Kim, K.P., Kim, Y.-K., Kislinger, T., Lässer, C., Lee, D.S.,
Lee, H., van Leeuwen, J., Lener, T., Liu, M.-L., Lötvall, J., Marcilla, A., Mathivanan,
S., Möller, A., Morhayim, J., Mullier, F., Nazarenko, I., Nieuwland, R., Nunes, D.N.,
Pang, K., Park, J., Patel, T., Pocsfalvi, G., Del Portillo, H., Putz, U., Ramirez, M.I.,
Rodrigues, M.L., Roh, T.-Y., Royo, F., Sahoo, S., Schiffelers, R., Sharma, S., Siljan-
der, P., Simpson, R.J., Soekmadji, C., Stahl, P., Stensballe, A., Stępień, E., Tahara, H.,
Trummer, A., Valadi, H., Vella, L.J., Wai, S.N., Witwer, K., Yáñez-Mó, M., Youn, H.,
Zeidler, R., Gho, Y.S., 2015. EVpedia: a community web portal for extracellular
vesicles research. Bioinformatics 31, 933–939. http://dx.doi.org/10.1093/bioin-
formatics/btu741.
Kim, H.-S., Choi, D.-Y., Yun, S.J., Choi, S.-M., Kang, J.W., Jung, J.W., Hwang, D., Kim, K.
P., Kim, D.-W., 2012. Proteomic analysis of microvesicles derived from human
mesenchymal stem cells. J. Proteome Res. 11, 839–849. http://dx.doi.org/
10.1021/pr200682z.
Koppers-Lalic, D., Hackenberg, M., Bijnsdorp, I.V., van Eijndhoven, M.A.J., Sadek, P.,
Sie, D., Zini, N., Middeldorp, J.M., Ylstra, B., de Menezes, R.X., Würdinger, T.,
Meijer, G.A., Pegtel, D.M., 2014. Nontemplated nucleotide additions distinguish
the small RNA composition in cells from exosomes. Cell Rep. 8, 1649–1658.
http://dx.doi.org/10.1016/j.celrep.2014.08.027.
Kordelas, L., Rebmann, V., Ludwig, A.-K., Radtke, S., Ruesing, J., Doeppner, T.R.,
Epple, M., Horn, P.A., Beelen, D.W., Giebel, B., 2014. MSC-derived exosomes: a
novel tool to treat therapy-refractory graft-versus-host disease. Leukemia 28,
970–973. http://dx.doi.org/10.1038/leu.2014.41.
Kowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J.P., Primdal-Bengtson, B., Dingli,
F., Loew, D., Tkach, M., Théry, C., 2016. Proteomic comparison deﬁnes novel
markers to characterize heterogeneous populations of extracellular vesicle
subtypes. Proc. Natl. Acad. Sci. USA 113, E968–E977. http://dx.doi.org/10.1073/
pnas.1521230113.
Lai, C.P., Mardini, O., Ericsson, M., Prabhakar, S., Maguire, C.A., Chen, J.W., Tannous,
B.A., Breakeﬁeld, X.O., 2014. Dynamic biodistribution of extracellular vesicles
in vivo using a multimodal imaging reporter. ACS Nano 8, 483–494. http://dx.
doi.org/10.1021/nn404945r.
Lai, R.C., Chen, T.S., Lim, S.K., 2011. Mesenchymal stem cell exosome: a novel stem
cell-based therapy for cardiovascular disease. Regen. Med. 6, 481–492. http:
//dx.doi.org/10.2217/rme.11.35.
Lässer, C., Alikhani, V.S., Ekström, K., Eldh, M., Paredes, P.T., Bossios, A., Sjöstrand,
M., Gabrielsson, S., Lötvall, J., Valadi, H., 2011. Human saliva, plasma and breast
milk exosomes contain RNA: uptake by macrophages. J. Transl. Med. 9, 9. http:
//dx.doi.org/10.1186/1479-5876-9-9.
Lener, T., Gimona, M., Aigner, L., Börger, V., Buzas, E., Camussi, G., Chaput, N.,
Chatterjee, D., Court, F.A., Del Portillo, H.A., O’Driscoll, L., Fais, S., Falcon-Perez, J.
M., Felderhoff-Mueser, U., Fraile, L., Gho, Y.S., Görgens, A., Gupta, R.C., Hendrix,
A., Hermann, D.M., Hill, A.F., Hochberg, F., Horn, P.A., de Kleijn, D., Kordelas, L.,
Kramer, B.W., Krämer-Albers, E.-M., Laner-Plamberger, S., Laitinen, S., Leonardi,
T., Lorenowicz, M.J., Lim, S.K., Lötvall, J., Maguire, C.A., Marcilla, A., Nazarenko, I.,
Ochiya, T., Patel, T., Pedersen, S., Pocsfalvi, G., Pluchino, S., Quesenberry, P.,
Reischl, I.G., Rivera, F.J., Sanzenbacher, R., Schallmoser, K., Slaper-Cortenbach, I.,
Strunk, D., Tonn, T., Vader, P., van Balkom, B.W.M., Wauben, M., Andaloussi, S. El,
Théry, C., Rohde, E., Giebel, B., 2015. Applying extracellular vesicles based
therapeutics in clinical trials - an ISEV position paper. J. Extracell. Vesicles 4,
30087.
Lindoso, R.S., Collino, F., Bruno, S., Araujo, D.S., Sant’Anna, J.F., Tetta, C., Provero, P.,
Quesenberry, P.J., Vieyra, A., Einicker-Lamas, M., Camussi, G., 2014. Extracellular
vesicles released from mesenchymal stromal cells modulate miRNA in renal
tubular cells and inhibit ATP depletion injury. Stem Cells Dev. 23, 1809–1819.
http://dx.doi.org/10.1089/scd.2013.0618.
Llorente, A., Skotland, T., Sylvänne, T., Kauhanen, D., Róg, T., Orłowski, A., Vattu-
lainen, I., Ekroos, K., Sandvig, K., 2013. Molecular lipidomics of exosomes re-
leased by PC-3 prostate cancer cells. Biochim. Biophys. Acta 1831, 1302–1309.
Lopatina, T., Bruno, S., Tetta, C., Kalinina, N., Porta, M., Camussi, G., 2014. Platelet-
derived growth factor regulates the secretion of extracellular vesicles by adi-
pose mesenchymal stem cells and enhances their angiogenic potential. Cell
S. Bruno et al. / European Journal of Pharmacology 790 (2016) 83–91 91Commun. Signal. 12, 26. http://dx.doi.org/10.1186/1478-811X-12-26.
Lötvall, J., Hill, A.F., Hochberg, F., Buzás, E.I., Di Vizio, D., Gardiner, C., Gho, Y.S.,
Kurochkin, I.V., Mathivanan, S., Quesenberry, P., Sahoo, S., Tahara, H., Wauben,
M.H., Witwer, K.W., Théry, C., 2014. Minimal experimental requirements for
deﬁnition of extracellular vesicles and their functions: a position statement
from the International Society for Extracellular Vesicles. J. Extracell. Vesicles 3,
26913.
Lugini, L., Cecchetti, S., Huber, V., Luciani, F., Macchia, G., Spadaro, F., Paris, L.,
Abalsamo, L., Colone, M., Molinari, A., Podo, F., Rivoltini, L., Ramoni, C., Fais, S.,
2012. Immune surveillance properties of human NK cell-derived exosomes. J.
Immunol. 189, 2833–2842. http://dx.doi.org/10.4049/jimmunol.1101988.
Mathivanan, S., Ji, H., Simpson, R.J., 2010. Exosomes: extracellular organelles im-
portant in intercellular communication. J. Proteom. 73, 1907–1920. http://dx.
doi.org/10.1016/j.jprot.2010.06.006.
Merino-González, C., Zuñiga, F.A., Escudero, C., Ormazabal, V., Reyes, C., Nova-
Lamperti, E., Salomón, C., Aguayo, C., 2016. Mesenchymal stem cell-derived
extracellular vesicles promote angiogenesis: potencial clinical application.
Front. Physiol. 7, 24. http://dx.doi.org/10.3389/fphys.2016.00024.
Miranda, K.C., Bond, D.T., Levin, J.Z., Adiconis, X., Sivachenko, A., Russ, C., Brown, D.,
Nusbaum, C., Russo, L.M., 2014. Massively parallel sequencing of human urinary
exosome/microvesicle RNA reveals a predominance of non-coding RNA. PLoS
One 9, e96094. http://dx.doi.org/10.1371/journal.pone.0096094.
Nakano, I., Garnier, D., Minata, M., Rak, J., 2015. Extracellular vesicles in the biology
of brain tumour stem cells–Implications for inter-cellular communication,
therapy and biomarker development. Semin. Cell Dev. Biol. 40, 17–26. http://dx.
doi.org/10.1016/j.semcdb.2015.02.011.
Nawaz, M., Fatima, F., Vallabhaneni, K.C., Penfornis, P., Valadi, H., Ekström, K.,
Kholia, S., Whitt, J.D., Fernandes, J.D., Pochampally, R., Squire, J.A., Camussi, G.,
2016. Extracellular vesicles: evolving factors in stem cell biology. Stem Cells Int.
2016, 1073140. http://dx.doi.org/10.1155/2016/1073140.
Oosthuyzen, W., Scullion, K.M., Ivy, J.R., Morrison, E.E., Hunter, R.W., Starkey Lewis,
P.J., O’Duibhir, E., Street, J.M., Caporali, A., Gregory, C.D., Forbes, S.J., Webb, D.J.,
Bailey, M.A., Dear, J.W., 2016. Vasopressin regulates extracellular vesicle uptake
by kidney collecting duct cells. J. Am. Soc. Nephrol. . http://dx.doi.org/10.1681/
ASN.2015050568
Pisitkun, T., Shen, R.-F., Knepper, M.A., 2004. Identiﬁcation and proteomic proﬁling
of exosomes in human urine. Proc. Natl. Acad. Sci. 101, 13368–13373. http://dx.
doi.org/10.1073/pnas.0403453101.
Pocsfalvi, G., Raj, D.A.A., Fiume, I., Vilasi, A., Trepiccione, F., Capasso, G., 2015. Ur-
inary extracellular vesicles as reservoirs of altered proteins during the patho-
genesis of polycystic kidney disease. Proteom. Clin. Appl. 9, 552–567. http://dx.
doi.org/10.1002/prca.201400199.
Potolicchio, I., Carven, G.J., Xu, X., Stipp, C., Riese, R.J., Stern, L.J., Santambrogio, L.,
2005. Proteomic analysis of microglia-derived exosomes: metabolic role of the
aminopeptidase CD13 in neuropeptide catabolism. J. Immunol. 175, 2237–2243.
Quesenberry, P.J., Aliotta, J., Camussi, G., Abdel-Mageed, A.B., Wen, S., Goldberg, L.,
Zhang, H.-G., Tetta, C., Franklin, J., Coffey, R.J., Danielson, K., Subramanya, V.,
Ghiran, I., Das, S., Chen, C.C., Pusic, K.M., Pusic, A.D., Chatterjee, D., Kraig, R.P.,
Balaj, L., Dooner, M., 2015. Potential functional applications of extracellular
vesicles: a report by the NIH common fund extracellular RNA communication
consortium. J. Extracell. Vesicles 4, 27575.
Quesenberry, P.J., Goldberg, L.R., Aliotta, J.M., Dooner, M.S., Pereira, M.G., Wen, S.,
Camussi, G., 2014. Cellular phenotype and extracellular vesicles: basic and
clinical considerations. Stem Cells Dev. 23, 1429–1436. http://dx.doi.org/
10.1089/scd.2013.0594.
Raiborg, C., Stenmark, H., 2009. The ESCRT machinery in endosomal sorting of
ubiquitylated membrane proteins. Nature 458, 445–452. http://dx.doi.org/
10.1038/nature07961.
Rak, J., Guha, A., 2012. Extracellular vesicles–vehicles that spread cancer genes.
Bioessays 34, 489–497. http://dx.doi.org/10.1002/bies.201100169.
Ranghino, A., Dimuccio, V., Papadimitriou, E., Bussolati, B., 2015. Extracellular ve-
sicles in the urine: markers and mediators of tissue damage and regeneration.
Clin. Kidney J. 8, 23–30. http://dx.doi.org/10.1093/ckj/sfu136.
Ratajczak, J., Miekus, K., Kucia, M., Zhang, J., Reca, R., Dvorak, P., Ratajczak, M.Z.,
2006. Embryonic stem cell-derived microvesicles reprogram hematopoietic
progenitors: evidence for horizontal transfer of mRNA and protein delivery.
Leukemia 20, 847–856. http://dx.doi.org/10.1038/sj.leu.2404132.
Ratajczak, M.Z., Ratajczak, J., 2016. Horizontal transfer of RNA and proteins between
cells by extracellular microvesicles: 14 years later. Clin. Transl. Med 5, 7. http:
//dx.doi.org/10.1186/s40169-016-0087-4.
Record, M., Subra, C., Silvente-Poirot, S., Poirot, M., 2011. Exosomes as intercellular
signalosomes and pharmacological effectors. Biochem. Pharmacol. 81,
1171–1182. http://dx.doi.org/10.1016/j.bcp.2011.02.011.
Reis, L.A., Borges, F.T., Simões, M.J., Borges, A.A., Sinigaglia-Coimbra, R., Schor, N.,
2012. Bone marrow-derived mesenchymal stem cells repaired but did not
prevent gentamicin-induced acute kidney injury through paracrine effects inrats. PLoS One 7, e44092. http://dx.doi.org/10.1371/journal.pone.0044092.
Robbins, P.D., Morelli, A.E., 2014. Regulation of immune responses by extracellular
vesicles. Nat. Rev. Immunol. 14, 195–208. http://dx.doi.org/10.1038/nri3622.
Salih, M., Zietse, R., Hoorn, E.J., 2014. Urinary extracellular vesicles and the kidney:
biomarkers and beyond. Am. J. Physiol. Ren. Physiol. 306, F1251–F1259. http:
//dx.doi.org/10.1152/ajprenal.00128.2014.
Street, J.M., Birkhoff, W., Menzies, R.I., Webb, D.J., Bailey, M.A., Dear, J.W., 2011.
Exosomal transmission of functional aquaporin 2 in kidney cortical collecting
duct cells. J. Physiol. 589, 6119–6127. http://dx.doi.org/10.1113/
jphysiol.2011.220277.
Sun, D., Zhuang, X., Xiang, X., Liu, Y., Zhang, S., Liu, C., Barnes, S., Grizzle, W., Miller,
D., Zhang, H.-G., 2010. A novel nanoparticle drug delivery system: the anti-
inﬂammatory activity of curcumin is enhanced when encapsulated in exo-
somes. Mol. Ther. 18, 1606–1614. http://dx.doi.org/10.1038/mt.2010.105.
Taylor, D.D., Shah, S., 2015. Methods of isolating extracellular vesicles impact down-
stream analyses of their cargoes. Methods 87, 3–10. http://dx.doi.org/10.1016/j.
ymeth.2015.02.019.
Tian, Y., Li, S., Song, J., Ji, T., Zhu, M., Anderson, G.J., Wei, J., Nie, G., 2014. A doxor-
ubicin delivery platform using engineered natural membrane vesicle exosomes
for targeted tumor therapy. Biomaterials 35, 2383–2390. http://dx.doi.org/
10.1016/j.biomaterials.2013.11.083.
Tomasoni, S., Longaretti, L., Rota, C., Morigi, M., Conti, S., Gotti, E., Capelli, C., Introna,
M., Remuzzi, G., Benigni, A., 2013. Transfer of growth factor receptor mRNA via
exosomes unravels the regenerative effect of mesenchymal stem cells. Stem
Cells Dev. 22, 772–780. http://dx.doi.org/10.1089/scd.2012.0266.
Turturici, G., Tinnirello, R., Sconzo, G., Geraci, F., 2014. Extracellular membrane
vesicles as a mechanism of cell-to-cell communication: advantages and dis-
advantages. Am. J. Physiol. Cell Physiol. 306, C621–C633. http://dx.doi.org/
10.1152/ajpcell.00228.2013.
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J.J., Lötvall, J.O., 2007. Exo-
some-mediated transfer of mRNAs and microRNAs is a novel mechanism of
genetic exchange between cells. Nat. Cell Biol. 9, 654–659. http://dx.doi.org/
10.1038/ncb1596.
van Koppen, A., Joles, J.A., van Balkom, B.W.M., Lim, S.K., de Kleijn, D., Giles, R.H.,
Verhaar, M.C., 2012. Human embryonic mesenchymal stem cell-derived con-
ditioned medium rescues kidney function in rats with established chronic
kidney disease. PLoS One 7, e38746. http://dx.doi.org/10.1371/journal.
pone.0038746.
Wang, D., Sun, W., 2014. Urinary extracellular microvesicles: isolation methods and
prospects for urinary proteome. Proteomics 14, 1922–1932. http://dx.doi.org/
10.1002/pmic.201300371.
Wang, Q., Zhuang, X., Mu, J., Deng, Z.-B., Jiang, H., Zhang, L., Xiang, X., Wang, B., Yan,
J., Miller, D., Zhang, H.-G., 2013. Delivery of therapeutic agents by nanoparticles
made of grapefruit-derived lipids. Nat. Commun. 4, 1867. http://dx.doi.org/
10.1038/ncomms2886.
Wiklander, O.P.B., Nordin, J.Z., O’Loughlin, A., Gustafsson, Y., Corso, G., Mäger, I.,
Vader, P., Lee, Y., Sork, H., Seow, Y., Heldring, N., Alvarez-Erviti, L., Smith, C.I.E.,
Le Blanc, K., Macchiarini, P., Jungebluth, P., Wood, M.J.A., Andaloussi, S. El, 2015.
Extracellular vesicle in vivo biodistribution is determined by cell source, route
of administration and targeting. J. Extracell. Vesicles 4, 26316.
Witwer, K.W., Buzás, E.I., Bemis, L.T., Bora, A., Lässer, C., Lötvall, J., Nolte-’t Hoen, E.
N., Piper, M.G., Sivaraman, S., Skog, J., Théry, C., Wauben, M.H., Hochberg, F.,
2013. Standardization of sample collection, isolation and analysis methods in
extracellular vesicle research. J. Extracell. Vesicles, 2. http://dx.doi.org/10.3402/
jev.v2i0.20360.
Zaborowski, M.P., Balaj, L., Breakeﬁeld, X.O., Lai, C.P., 2015. Extracellular vesicles:
composition, biological relevance, and methods of study. Bioscience 65,
783–797. http://dx.doi.org/10.1093/biosci/biv084.
Zhan, C., Ma, C., Yuan, H., Cao, B., Zhu, J., 2015. Macrophage-derived microvesicles
promote proliferation and migration of Schwann cell on peripheral nerve re-
pair. Biochem. Biophys. Res. Commun. 468, 343–348. http://dx.doi.org/10.1016/
j.bbrc.2015.10.097.
Zhou, H., Pisitkun, T., Aponte, A., Yuen, P.S.T., Hoffert, J.D., Yasuda, H., Hu, X., Chawla,
L., Shen, R.-F., Knepper, M.A., Star, R.A., 2006. Exosomal Fetuin-A identiﬁed by
proteomics: a novel urinary biomarker for detecting acute kidney injury. Kid-
ney Int. 70, 1847–1857. http://dx.doi.org/10.1038/sj.ki.5001874.
Zhou, Y., Xu, H., Xu, W., Wang, B., Wu, H., Tao, Y., Zhang, B., Wang, M., Mao, F., Yan,
Y., Gao, S., Gu, H., Zhu, W., Qian, H., 2013. Exosomes released by human um-
bilical cord mesenchymal stem cells protect against cisplatin-induced renal
oxidative stress and apoptosis in vivo and in vitro. Stem Cell Res. Ther. 4, 34.
http://dx.doi.org/10.1186/scrt194.
Zou, X., Zhang, G., Cheng, Z., Yin, D., Du, T., Ju, G., Miao, S., Liu, G., Lu, M., Zhu, Y.,
2014. Microvesicles derived from human Wharton's Jelly mesenchymal stromal
cells ameliorate renal ischemia-reperfusion injury in rats by suppressing
CX3CL1. Stem Cell Res. Ther. 5, 40. http://dx.doi.org/10.1186/scrt428.
